GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00518976 | Oral cavity | OSCC | positive regulation of protein kinase B signaling | 61/7305 | 120/18723 | 5.52e-03 | 2.14e-02 | 61 |
GO:000680915 | Oral cavity | OSCC | nitric oxide biosynthetic process | 41/7305 | 76/18723 | 5.78e-03 | 2.22e-02 | 41 |
GO:20004013 | Oral cavity | OSCC | regulation of lymphocyte migration | 34/7305 | 61/18723 | 5.90e-03 | 2.25e-02 | 34 |
GO:00486596 | Oral cavity | OSCC | smooth muscle cell proliferation | 89/7305 | 184/18723 | 5.95e-03 | 2.27e-02 | 89 |
GO:0046642 | Oral cavity | OSCC | negative regulation of alpha-beta T cell proliferation | 10/7305 | 13/18723 | 6.32e-03 | 2.35e-02 | 10 |
GO:00704247 | Oral cavity | OSCC | regulation of nucleotide-binding oligomerization domain containing signaling pathway | 10/7305 | 13/18723 | 6.32e-03 | 2.35e-02 | 10 |
GO:00108835 | Oral cavity | OSCC | regulation of lipid storage | 32/7305 | 57/18723 | 6.45e-03 | 2.40e-02 | 32 |
GO:00706462 | Oral cavity | OSCC | protein modification by small protein removal | 77/7305 | 157/18723 | 6.55e-03 | 2.43e-02 | 77 |
GO:19021075 | Oral cavity | OSCC | positive regulation of leukocyte differentiation | 77/7305 | 157/18723 | 6.55e-03 | 2.43e-02 | 77 |
GO:19037085 | Oral cavity | OSCC | positive regulation of hemopoiesis | 77/7305 | 157/18723 | 6.55e-03 | 2.43e-02 | 77 |
GO:00605629 | Oral cavity | OSCC | epithelial tube morphogenesis | 149/7305 | 325/18723 | 6.73e-03 | 2.50e-02 | 149 |
GO:0023035 | Oral cavity | OSCC | CD40 signaling pathway | 11/7305 | 15/18723 | 7.49e-03 | 2.75e-02 | 11 |
GO:0033138 | Oral cavity | OSCC | positive regulation of peptidyl-serine phosphorylation | 55/7305 | 108/18723 | 7.75e-03 | 2.84e-02 | 55 |
GO:00082024 | Oral cavity | OSCC | steroid metabolic process | 146/7305 | 319/18723 | 7.78e-03 | 2.85e-02 | 146 |
GO:00016594 | Oral cavity | OSCC | temperature homeostasis | 84/7305 | 174/18723 | 7.84e-03 | 2.87e-02 | 84 |
GO:00702653 | Oral cavity | OSCC | necrotic cell death | 34/7305 | 62/18723 | 8.23e-03 | 3.00e-02 | 34 |
GO:00341424 | Oral cavity | OSCC | toll-like receptor 4 signaling pathway | 25/7305 | 43/18723 | 8.52e-03 | 3.09e-02 | 25 |
GO:00434107 | Oral cavity | OSCC | positive regulation of MAPK cascade | 213/7305 | 480/18723 | 8.71e-03 | 3.16e-02 | 213 |
GO:0050691 | Oral cavity | OSCC | regulation of defense response to virus by host | 24/7305 | 41/18723 | 8.81e-03 | 3.19e-02 | 24 |
GO:00435062 | Oral cavity | OSCC | regulation of JUN kinase activity | 32/7305 | 58/18723 | 9.08e-03 | 3.26e-02 | 32 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
hsa05010210 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa05020210 | Esophagus | ESCC | Prion disease | 193/4205 | 273/8465 | 6.42e-13 | 1.34e-11 | 6.89e-12 | 193 |
hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa0421027 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
hsa05170210 | Esophagus | ESCC | Human immunodeficiency virus 1 infection | 147/4205 | 212/8465 | 3.37e-09 | 3.53e-08 | 1.81e-08 | 147 |
hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa0513526 | Esophagus | ESCC | Yersinia infection | 100/4205 | 137/8465 | 1.80e-08 | 1.59e-07 | 8.12e-08 | 100 |
hsa05171211 | Esophagus | ESCC | Coronavirus disease - COVID-19 | 156/4205 | 232/8465 | 3.18e-08 | 2.68e-07 | 1.37e-07 | 156 |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TNF | SNV | Missense_Mutation | rs373646181 | c.481N>A | p.Val161Ile | p.V161I | P01375 | protein_coding | tolerated(0.2) | benign(0) | TCGA-CM-4752-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TNF | SNV | Missense_Mutation | novel | c.186N>T | p.Glu62Asp | p.E62D | P01375 | protein_coding | tolerated(0.08) | possibly_damaging(0.67) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TNF | SNV | Missense_Mutation | rs369510319 | c.473N>A | p.Arg158His | p.R158H | P01375 | protein_coding | deleterious(0.03) | probably_damaging(0.98) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TNF | SNV | Missense_Mutation | rs373646181 | c.481N>A | p.Val161Ile | p.V161I | P01375 | protein_coding | tolerated(0.2) | benign(0) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNF | SNV | Missense_Mutation | novel | c.607N>A | p.Glu203Lys | p.E203K | P01375 | protein_coding | tolerated(0.13) | benign(0.031) | TCGA-EO-A22T-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNF | SNV | Missense_Mutation | novel | c.341N>T | p.Ala114Val | p.A114V | P01375 | protein_coding | tolerated(0.16) | benign(0.267) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TNF | SNV | Missense_Mutation | rs777874746 | c.169G>A | p.Gly57Ser | p.G57S | P01375 | protein_coding | deleterious(0.03) | probably_damaging(0.995) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
TNF | insertion | Frame_Shift_Ins | novel | c.315_316insGGTTTGGGTTTGGGGGT | p.Asn106GlyfsTer20 | p.N106Gfs*20 | P01375 | protein_coding | | | TCGA-B5-A5OD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD |
TNF | insertion | Frame_Shift_Ins | novel | c.316_317insGGGTTAGT | p.Asn106ArgfsTer17 | p.N106Rfs*17 | P01375 | protein_coding | | | TCGA-B5-A5OD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD |
TNF | SNV | Missense_Mutation | | c.291N>T | p.Gln97His | p.Q97H | P01375 | protein_coding | deleterious(0.05) | benign(0.161) | TCGA-ED-A459-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Ancillary | alvesin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | HYDROXYCHLOROQUINE | HYDROXYCHLOROQUINE | 9002011 |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | MIDAZOLAM | MIDAZOLAM | 16406030 |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | SODIUM CROMOGLYCATE | | 7554404 |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | CYT-609 | | 20876255 |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | ABT-122 | REMTOLUMAB | |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | rifampin | RIFAMPIN | 22151084 |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | DLX-105 | | |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | PRAZOSIN HYDROCHLORIDE | | 11406472 |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | CEFOTAXIME | CEFOTAXIME | 8354907,10989981 |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | CPL-7075 | LENABASUM | |